Dr Reddy's Laboratories gains nearly 2% on drug launch in US market

Esomeprazole is an OTC proton pump inhibitor used to treat frequent heartburn occurring two or more days a week in adults.

Shares of Dr Reddy's Laboratoriesgained nearly 2 percent intraday Friday as company launched a capsules to treat frequent heartburn.

The company announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter (OTC) in the United States market as approved by the US Food and Drug Administration (USFDA).

Esomeprazole Magnesium Delayed-Release Capsules is a therapeutic equivalent generic version of Nexium 24HR Capsules.

Esomeprazole is an OTC proton pump inhibitor used to treat frequent heartburn occurring two or more days a week in adults.

Milan Kalawadia, Vice President and Head, US OTC and Speciality Rx businesses at Dr Reddy's Laboratories said, "This launch continues to demonstrate our deep R&D and manufacturing capabilities to bring newer storebrand OTC medications to the market."

At 11:12 hrs Dr Reddy’s Laboratories was quoting at Rs 2,067.60, up Rs 36.70, or 1.81 percent on the BSE.

Two days Free Trials and best services packages for dealing in Stock market click here to get >> Nifty Market Tips and Ripples Advisory One Missed call on @9644405056